Translating leukemia stem cells into the clinical setting: Harmonizing the heterogeneity

Area of Science:

• Hematology
• Cancer Biology
• Stem Cell Research

Background:

• Leukemia stem cells (LSCs) are implicated in acute myeloid leukemia (AML) maintenance and relapse.
• Traditionally, LSCs were identified by their ability to engraft in mice, often associated with a CD34+CD38- hematopoietic stem cell (HSC) phenotype.
• Recent findings reveal heterogeneity in LSC phenotypes and their engraftment capabilities.

Purpose of the Study:

• To investigate the relationship between the immaturity of AML cell phenotypes and clinical outcomes.
• To determine if the most primitive AML cell phenotype can serve as a biomarker for clinically relevant LSCs.

Main Methods:

• Analysis of AML cell phenotypes, focusing on immaturity markers like CD34, CD38, and aldehyde dehydrogenase activity.
• Correlation of observed phenotypes with clinical data, including complete remission rates, event-free survival, and overall survival.

Main Results:

• A heterogeneous distribution of primitive phenotypes was observed within AML samples.
• Patients with AML cells exhibiting a primitive HSC phenotype (CD34+CD38- with high aldehyde dehydrogenase activity) had significantly lower remission rates and poorer survival.
• AML with more mature primitive cell phenotypes was associated with better clinical outcomes.

Conclusions:

• The immaturity of the most primitive AML cell phenotype correlates strongly with clinical outcomes.
• This primitive phenotype may serve as a valuable biomarker for identifying clinically relevant LSCs in AML patients.
• Understanding LSC heterogeneity is crucial for predicting AML prognosis and guiding treatment strategies.